<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171468</url>
  </required_header>
  <id_info>
    <org_study_id>1160.61</org_study_id>
    <nct_id>NCT02171468</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects</brief_title>
  <official_title>Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate and compare pharmacokinetics, safety and pharmacodynamics of dabigatran&#xD;
      etexilate following oral administration of multiple doses (110 mg and 150 mg b.i.d., 7 days)&#xD;
      in healthy male subjects between Japanese and Caucasians&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in QT(c) intervals</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the concentration-time curve over a uniform dosing interval τ after administration of single dose on Day 1)</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,ss (time from last dosing to maximum concentration at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum concentration at steady state over a uniform dosing interval τ)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,ss (terminal rate constant at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss (terminal half-life at steady state)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,ss (mean residence time in the body at steady state after oral administration)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss (apparent clearance in the plasma at steady state after extravascular multiple dose administration)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax,13 (accumulation ratio calculated as Cmax,ss/Cmax)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC,13 (accumulation ratio calculated as AUCτ,ss/AUCτ,1)</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve for activated partial thromboplastin time (aPTT)</measure>
    <time_frame>0 - 12 hours after adminstration on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve for ecarin clotting time (ECT)</measure>
    <time_frame>0 - 12 hours after adminstration on day 1 and day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of trough concentrations</measure>
    <time_frame>after doses 3, 5, 7, 9, 11 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of trough concentrations morning versus evening</measure>
    <time_frame>after doses 9, 10, 11, 12, 13</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran high dose</intervention_name>
    <arm_group_label>Dabigatran high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran low dose</intervention_name>
    <arm_group_label>Dabigatran low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Japanese or Caucasian healthy male subjects according to the following criteria:&#xD;
&#xD;
             Based upon a complete medical history, including the physical examination, vital signs&#xD;
             (blood pressure, pulse rate and body temperature), 12-lead electrocardiogram, clinical&#xD;
             laboratory tests&#xD;
&#xD;
               -  No finding of clinical relevance&#xD;
&#xD;
               -  No evidence of a clinically relevant concomitant disease&#xD;
&#xD;
               -  Caucasian subjects are from a well-defined Caucasian population, both parents of&#xD;
                  Caucasians, the subjects can understand the subject information for informed&#xD;
                  consent in English and the subjects have lived 8 or less than 8 years in Japan&#xD;
&#xD;
          2. Age: ≥20 and ≤45 years&#xD;
&#xD;
          3. Body mass index (BMI): ≥18.5 and ≤29.9 kg/m2&#xD;
&#xD;
          4. Signed and dated written informed consent before admission to the trial site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          2. Subject can not use an adequate form of contraception from the time of the first dose&#xD;
             on Day 1 up to end-of study examination&#xD;
&#xD;
          3. Current diseases of the central nervous system (such as epilepsy), or psychiatric&#xD;
             disorders or neurological disorders&#xD;
&#xD;
          4. History of clinically significant orthostatic hypotension, clinically significant&#xD;
             current or past fainting spells or blackouts&#xD;
&#xD;
          5. Chronic or relevant acute infections&#xD;
&#xD;
          6. History of&#xD;
&#xD;
               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the&#xD;
                  safety assessment as judged by the investigator (excluding asymptomatic seasonal&#xD;
                  rhinitis/hay fever)&#xD;
&#xD;
               -  any bleeding disorder including prolonged or habitual bleeding&#xD;
&#xD;
               -  other hematologic diseases&#xD;
&#xD;
               -  cerebral bleeding (e.g. after a car accident)&#xD;
&#xD;
               -  concussions (head trauma resulting in injuring to brain) with or without loss of&#xD;
                  consciousness&#xD;
&#xD;
          7. Intake of drugs with a long half-life (&gt;24 hours) within at least 1 month or less than&#xD;
             10 half-lives, whichever is shorter, of the respective drug prior to administration or&#xD;
             during the trial&#xD;
&#xD;
          8. Use of aspirin (including over-the-counter medications), antipletelet agents like&#xD;
             ticlopidine or dipyridamole, chronic administration of nonsteroidal antiinflammatory&#xD;
             drugs , coumadin like anticoagulants, chronic use of corticosteroids, heparin or&#xD;
             fibrinolytic agents within 28 days prior to administration up to end-of-study&#xD;
             examination&#xD;
&#xD;
          9. Participation in another trial with an investigational drug within 3 months prior to&#xD;
             administration up to end-of-study examination&#xD;
&#xD;
         10. Smoker (&gt;10 cigarettes/day or inability to refrain from smoking during the trial)&#xD;
&#xD;
         11. Alcohol abuse (more than 60 g/day; confirmed by interview)&#xD;
&#xD;
         12. Drug abuse (confirmed by interview)&#xD;
&#xD;
         13. Blood donation (more than 100 mL from 3 months prior to screening and any blood&#xD;
             donation from screening up to end-of-study examination)&#xD;
&#xD;
         14. Excessive physical activities (within 7 days prior to the first drug administration up&#xD;
             to end-of-study examination)&#xD;
&#xD;
         15. Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
         16. Known hypersensitivity to the investigational drug or its excipients&#xD;
&#xD;
         17. Subject who was judged ineligible by the investigator or the sub-investigator&#xD;
&#xD;
         18. History of any familial bleeding disorder&#xD;
&#xD;
         19. Thrombocytes &lt;15 x 10**4 /microL&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1160/1160.61_U06-3420.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

